Technical Analysis for IOVA - Iovance Biotherapeutics, Inc.

Grade Last Price % Change Price Change
F 31.77 -7.08% -2.42
IOVA closed down 7.08 percent on Thursday, March 4, 2021, on 2.37 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical IOVA trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 200 DMA Bearish -7.08%
New Downtrend Bearish -7.08%
Wide Bands Range Expansion -7.08%
Oversold Stochastic Weakness -7.08%
New Downtrend Bearish -14.94%
Older End-of-Day Signals for IOVA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
2x Volume Pace about 10 hours ago
Down 5% about 10 hours ago
Fell Below Lower Bollinger Band about 10 hours ago
1.5x Volume Pace about 10 hours ago
Up 1% about 10 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Iovance Biotherapeutics, Inc. Description

Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immune System Immunotherapy Oncology Cancer Treatments Cancer Immunotherapy Melanoma Antineoplastic Drugs Cancer Cell Cell Therapy Head And Neck Cancer Checkpoint Inhibitor Solid Tumor Adoptive Cell Transfer Immunotherapy Product Metastatic Melanoma Cancer Immunotherapy Product Cancer Immunotherapy Products Head And Neck Cancers Immunotherapy Products National Cancer Institute Ocular Melanoma Breast And Lung Cancer Lymphocytes Pembrolizumab Treatment Of Metastatic Melanoma

Is IOVA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 54.2081
52 Week Low 18.7
Average Volume 1,204,373
200-Day Moving Average 36.90
50-Day Moving Average 46.14
20-Day Moving Average 43.67
10-Day Moving Average 38.68
Average True Range 3.01
ADX 28.36
+DI 13.39
-DI 42.77
Chandelier Exit (Long, 3 ATRs ) 43.99
Chandelier Exit (Short, 3 ATRs ) 40.29
Upper Bollinger Band 55.50
Lower Bollinger Band 31.83
Percent B (%b) 0.0
BandWidth 54.20
MACD Line -3.36
MACD Signal Line -2.06
MACD Histogram -1.3003
Fundamentals Value
Market Cap 4.66 Billion
Num Shares 147 Million
EPS -1.31
Price-to-Earnings (P/E) Ratio -24.29
Price-to-Sales 0.00
Price-to-Book 8.12
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 37.07
Resistance 3 (R3) 37.48 36.13 36.18
Resistance 2 (R2) 36.13 34.78 35.92 35.89
Resistance 1 (R1) 33.95 33.95 33.28 33.54 35.59
Pivot Point 32.60 32.60 32.26 32.39 32.60
Support 1 (S1) 30.42 31.25 29.75 30.01 27.95
Support 2 (S2) 29.07 30.42 28.86 27.65
Support 3 (S3) 26.89 29.07 27.36
Support 4 (S4) 26.48